Can a Pumpkin-Shaped Molecule Bring a Different Ending to "Breaking Bad"?

Speed, uppers, chalk, glass, crystal, or whatever you prefer to call them, can be instantly detected from biological fluids with a new portable kit that costs as little as $50. Scientists at the Center for Self-Assembly and Complexity, within the Institute for Basic Science (IBS, South Korea), in collaboration with Pohang University of Science and Technology (POSTECH), have devised the first methamphetamine and amphetamine sensor that can detect minute concentrations of these drugs from a single drop of urine in real-time. Published in the journal Chem, this simple and flexible sensor, which can be attached to a wristband and connected to an Android app via Bluetooth, could move drug screening from the labs to the streets.

Easy to synthesize and cheaper than heroin or cocaine, amphetamine-based drugs are the most abused drugs in the world, after cannabis. Conventional drug detection methods require a long time, as the sample must be taken into a lab for the analysis. It also needs experts to run the expensive equipment. The technology reported in this study is instead small, portable, cheap, fast and easy to use.

The idea for this technology came from the IBS chemist HWANG Ilha: "I was watching a TV news report on the usage of illegal drugs, and I thought to check what the chemical structure of methamphetamine looks like." Soon after, the scientist anticipated that the drug would form a tight complex with a family of hollow pumpkin-shaped molecules, called cucurbituril (CB) members. The team then discovered that cucurbit[7]uril (CB[7])'s empty cavity binds well with amphetamine-based drugs and can be used as the drug recognition unit of a sensor. Cucurbiturils' hollow chamber has already been studied for various technological uses, but this is the first device application in amphetamine-based drug detection.

Combining a transistor coated with CB[7], flexible materials, rechargeable batteries and a Bluetooth antenna, the research team developed a detector wristband connected to an app. In the presence of the drug, the molecular recognition between CB[7] and the drug molecule triggers an electrical signal which appears as a peak on the smartphone screen.

Current drug detection based on immunoassay or liquid chromatography/mass spectrometry techniques has a detection limit of about 10 ng/mL. On the contrary, the sensitivity of this new sensor is about 0.0001 ng/mL in water and 0.1 ng/mL in urine. Therefore, it is expected that this method will allow the detection of drug molecules in biological fluids, like urine and sweat, for a longer time after drug consumption.

"Real time detection of amphetamine drugs on location would bring a big change to society," explains another corresponding author, KIM Kimoon. "In the same way as police can use a breathalyzer to detect alcohol on the spot, we aim to achieve the same with this device."

False positives cannot be excluded yet, as urine contains a rich mixture of proteins and other metabolites that could affect the reading. Therefore, before commercializing it, clinical trials with drug users' biological fluids are necessary. The researchers have patented the technology and they will continue to do further research in the near future.

"Combining basic science with the latest technology, we can expect that this research will also lead to other new sensors, useful for our daily life," concludes the third corresponding author, OH Joon Hak. Indeed, the team is also keen on developing sensors for other kinds of drugs, as well as kits for the detection of dangerous substances, environmental monitoring, healthcare and safety.

Yoonjung Jang, Moonjeong Jang, Hyoeun Kim, Sang Jin Lee, Eunyeong Jin, Jin Young Koo, In-Chul Hwang, Yonghwi Kim, Young Ho Ko, Ilha Hwang, Joon Hak Oh, Kimoon Kim.
Point-of-Use Detection of Amphetamine-Type Stimulants with Host-Molecule-Functionalized Organic Transistors.
Chem, 28 September 2017, doi: 10.1016/j.chempr.2017.08.015.

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...